Omalizumab for the treatment of atopic dermatitis

Eguiluz‐Gracia, Ibon; Robledo-Echarren, T.; Suarez-Fern, Ricardo; ez,; Fern, Montserrat; Ramon, ez-Rivas Silvia Sanchez

doi:10.4155/cli.14.108

Cited by 4 publications

(5 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of omalizumab in patients with AD has been presented in multiple case series and case reports. 42 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 Details on these cases are summarised in Table 1 . Patients across regions with average age ranging between 7 and 51 years, extremely variable levels of baseline IgE, and omalizumab (150–600 mg q2w or q4w) treatment duration between 8 and 292 weeks, have been studied.…”

Section: Anti-ige Therapy In Atopic Dermatitismentioning

confidence: 99%

“…The majority of studies report a high proportion of patients, with varying demographics and disease characteristics but mostly high-to-very high IgE levels, exhibiting improvements in the SCORAD index after omalizumab treatment. 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 In various case series studying ≥10 patients, a cumulative total of 83 patients out of the 101 patients showed clinical efficacy with omalizuamb. The largest case series reporting 24 patients with AD treated with omalizumab, all except one were reported to have improved.…”

Section: Anti-ige Therapy In Atopic Dermatitismentioning

confidence: 99%

See 1 more Smart Citation

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Wollenberg

Thomsen

Lacour

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

Immunoglobulin E (IgE) plays an essential role in many allergic diseases. This review highlights the role of IgE in atopic dermatitis (AD), a common, chronic, and complex skin inflammation, and the available therapeutic approaches that target IgE in AD. We examine the existing data showing the use of omalizumab, the only biologic anti-IgE therapy available in clinical use, plasma apheresis, and a combination of both therapeutic approaches for the treatment of AD. Existing data on the efficacy of omalizumab in AD are inconclusive. A limited number of randomised controlled studies, few uncontrolled prospective and retrospective reports, as well as multiple case series and case reports observed varying degrees of the efficacy of omalizumab in AD. Omalizumab displays a trend of higher efficacy in AD patients with low IgE levels compared with those with very high-to-extremely high serum IgE concentrations. Plasma apheresis and its combination with omalizumab show good efficacy, even in patients with unusually high serum IgE concentrations. Combining apheresis and anti-IgE treatment may serve as a comprehensive therapeutic approach for patients with elevated levels of IgE. Dedicated clinical studies with robust study designs are needed to establish the therapeutic efficacy of omalizumab in AD.

show abstract

Section: Anti-ige Therapy In Atopic Dermatitismentioning

confidence: 99%

Section: Anti-ige Therapy In Atopic Dermatitismentioning

confidence: 99%

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Wollenberg

Thomsen

Lacour

et al. 2021

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“…El omalizumab está indicado para el tratamiento de la urticaria crónica y el asma, pero particularmente en la DA no ha mostrado ser un medicamento que genere impacto en su evolución. No obstante, sí se ha reportado de gran utilidad en pacientes que tienen asma como comorbilidad presentando mejoría de los síntomas respiratorios, lo que podría explicar su uso en nuestro grupo de pacientes (45).…”

Section: Discussionunclassified

“…En cuanto al uso de productos biológicos, en el momento de la selección de los pacientes aún no se había autorizado en el país el dupilumab (anticuerpo monoclonal aprobado para el tratamiento de la dermatitis atópica) 44 , y solo se empleaba el omalizumab en pacientes que también presentaban asma. Este medicamento está indicado para el tratamiento de la urticaria crónica y el asma, pero en la dermatitis atópica no ha demostrado un efecto palpable, aunque sí se ha reportado su gran utilidad en pacientes que también tienen asma, cuyos síntomas respiratorios mejoran 45 .…”

Section: Discussionunclassified

Caracterización clínica, sociodemográfica y determinación del impacto en la calidad de vida de pacientes con dermatitis atópica de la ciudad de Medellín y su área metropolitana

2021

View full text Add to dashboard Cite

Introducción. La dermatitis atópica es una enfermedad cutánea crónica, intermitente muy frecuente y supone un impacto clínico y en la calidad de la vida de los pacientes. A la fecha no existen estudios locales en los que se describan las características generales de la misma en nuestra población. Objetivo. Evaluar las características sociodemográficas, clínicas y de calidad de vida en pacientes con dermatitis atópica de la ciudad de Medellín y su área metropolitana. Materiales y métodos. Estudio transversal descriptivo con pacientes que consultaran a algunos centros de referencia de la ciudad de Medellín, se les aplicó una encuesta con variables sociodemográficas y clínicas. Adicionalmente se aplicaron escalas de evaluación de la gravedad clínica y de calidad de vida. Resultados. Se incluyeron 113 pacientes. 36,3% manifestaron algún trastorno del sueño, 38,1% déficit de atención; 44,2% reportaron asma en la infancia. De la gravedad clínica el EASI tuvo un puntaje promedio de 6,9 y el SCORAD de 32,4, indicando un compromiso leve-moderado. En el Skindex-29 se encontró un promedio para dominios sintomático, emocional y funcional de 37,7, 25,09 y 16,9, respectivamente, con un promedio total de 24,78. Del EQ-5D el componente más alterado fue la presencia de dolor o malestar (17,6%) y la presencia de ansiedad o depresión (12,1%). Conclusión. Los resultados obtenidos confirman que nuestra población con dermatitis atópica presenta características similares a las reportadas en otras partes del mundo, resaltando el compromiso en los adultos y el impacto que ésta tiene sobre componentes neuropsiquiátricos y emocionales como el sueño.

show abstract

“…These actions prevent release of mediators from mentioned cells and resolve the clinical manifestations (4). Xolair is approved by food and drug administration (FDA) for children above 12 years with moderate to severe asthma, of course, in Europe, approved for 6 -12 years old with the same disease (5,6). There is a great challenge for use of Xolair in other allergic disorders such as AD.…”

Section: Contextmentioning

confidence: 99%

Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article

Ghaffari

2017

J Pediatr Rev

View full text Add to dashboard Cite

Context: Atopic dermatitis is a chronic skin disease in children. The prevalence of eczema is up to 30% in the world. Omalizumab (Xolair) is a monoclonal antibody that blocks the serum IgE. The aim of this study is to review the effect of Xolair in children with atopic dermatitis. Evidence Acquisition: The data was searched in PubMed, Scopus, and Embase with keywords: atopic dermatitis, eczema, children, pediatrics, Xolair, and Omalizumab. The inclusion criteria included articles related to use of Xolair in children with atopic dermatitis, under the age of 20 years old, as well a both full text and brief articles. The exclusion criteria were purely adult cases who had taken systemic immunosuppressive drugs and abstract article. There was no time limitation for our search. Results: After evaluating all data and a total of 124 searched articles, we found 8 eligible articles for this review. All of them had severe atopic dermatitis except 2 cases, which had moderate severity. Serum IgE level was increased in all patients. Only one of those studies included a control group. All patients were associated with other allergic disorders such as asthma and allergic rhinitis. Conclusions: Omalizumab (Xolair) is a safe drug, which decreases serum IgE level, scoring atopic dermatitis, as well as clinical manifestations in all of severe atopic dermatitis. However, in order to approve it, we need future clinical trial studies with control group.

show abstract

Omalizumab for the treatment of atopic dermatitis

Cited by 4 publications

References 119 publications

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence

Caracterización clínica, sociodemográfica y determinación del impacto en la calidad de vida de pacientes con dermatitis atópica de la ciudad de Medellín y su área metropolitana

Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article

Contact Info

Product

Resources

About